Table 4.
Top 25 Drugs by Expenditures in Clinics in 2020
| Druga | 2020 Expenditures ($ Thousands) |
Percent Change From 2019 |
|---|---|---|
| Pembrolizumab | 7,130,200 | 34.5 |
| Nivolumab | 3,327,182 | –8.4 |
| Pegfilgrastim | 3,100,689 | –6.4 |
| Infliximab | 2,788,271 | –19.4 |
| Rituximab | 2,697,158 | –8.4 |
| Denosumab | 2,531,554 | 1.1 |
| Bevacizumab | 2,442,623 | –3.6 |
| Ocrelizumab | 2,373,185 | 15.4 |
| Aflibercept | 2,292,236 | 7,745.6 |
| Trastuzumab | 1,952,649 | –19.1 |
| Vedolizumab | 1,851,387 | 26.8 |
| Ranibizumab | 1,712,420 | –13.3 |
| Immune globulin | 1,652,048 | 3.9 |
| Erythropoietin alfa | 1,602,118 | –8.0 |
| Daratumumab | 1,494,808 | 11.1 |
| Atezolizumab | 1,366,641 | 40.1 |
| Pertuzumab | 1,321,437 | 2.3 |
| Inactivated influenza virus | 1,300,966 | 3.6 |
| Ibrutinib | 1,250,472 | 29.5 |
| Abatacept | 1,145,161 | 10.2 |
| Pemetrexed | 1,046,214 | 4.1 |
| Durvalumab | 1,040,264 | 16.0 |
| Ipilimumab | 947,036 | 12.4 |
| Vaccine, pneumococcal conjugateb | 930,678 | –13.2 |
| Bictegravir/emtricitabine/tenofovir alafenamide | 924,009 | 46.1 |
aFor each drug listed, the expenditures shown are the total for branded and generic products (including biosimilars) and of various dosage forms unless otherwise stated.
bIncludes both Prevnar (Pfizer Inc) and Pneumovax-23 (Merck & Co, Inc).